Goldan Keith A.

Chief Financial OfficerSyndax Pharmaceuticals Inc (SNDX) · full profile →Form 4 · filed Feb 6, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$43K
Net Open-Market Flow
-$43K
Transactions
5
4 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 6, 2026Sell(S)2K$20.62$43K144K
Feb 4, 2026Grant(A)31K$0146K
Feb 4, 2026Grant(A)22K$0115K
Jan 30, 2026Other(J)1K$8.48$10K94K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 4, 2026Grant(A)118K$20.43$2.4M118K

Transaction Codes

S
Open-market sale
A
Grant / award
J
Other acquisition / disposition

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-041497) within minutes of acceptance. Every field above traces to the original document. Verify it directly: